CRXTW Clarus Therapeutics Holdings, Inc. - Warrant 9/9/2026

Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.  This security was issued by Clarus Therapeutics Holdings, Inc., whose common stock symbol is CRXT.

$0.08
As of 07/08/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Warrants
Category3:  Operating Companies
GICS sector:  Health Care
Industry:  Drug Manufacturers—General
Index country:  USA
Country of incorporation:  
IPO date:  09/10/2021
Outstanding shares:  0
Average volume:  6,803
Market cap:   $0
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy